Phase III Study of PET-Directed Local and Systemic Therapy for Prostate Cancer Recurrence After Surgery
Led by ECOG-ACRIN Cancer Research Group · Updated on 2026-08-19
804
Participants Needed
341
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for prostate cancer patients who have experienced a return of cancer markers biochemical recurrence after prostate surgery. This phase III trial compares whether adding enhanced therapy apalutamide with abiraterone and prednisone to standard care radiation therapy and short-term hormone therapy improves outcomes for patients without signs of cancer spread outside the pelvis. For patients with evidence of cancer spread beyond the pelvis detected by PET imaging, the study also tests whether adding targeted radiation to enhanced therapy provides additional benefit.
Participants undergo baseline PET scans to identify the presence or absence of cancer spread outside the pelvis. Based on these results, they are randomly assigned to one of four treatment groups involving combinations of standard external radiation therapy, androgen deprivation therapies such as goserelin, leuprolide, triptorelin, relugolix, or degarelix, apalutamide taken daily by mouth, and for some, additional targeted radiation to metastatic sites. Treatments generally continue for six months unless disease progression or side effects occur. Patients may undergo additional PET imaging during the study to monitor response.
Throughout the trial, participants will have regular follow-up visits every three months for two years, then every six months for years three to five, and annually up to ten years. Assessments include imaging scans, blood tests for prostate-specific antigen PSA, and quality-of-life evaluations using standardized questionnaires focusing on fatigue, pain, and cognitive function. Researchers will measure progression-free survival, overall survival, incidence of side effects, and quality of life up to ten years after treatment begins.
CONDITIONS
Brief Title
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Radiation + STAD + Apalutamide
Radiation + STAD
(control arm)
Current standard salvage RT + ADT
what it is
Salvage EBRT plus STAD with addition of apalutamide
Does not test addition of newer agents; standard without intensification
General guideline applies broadly but individual benefit may vary; not specific to PET‑guided BCR stratification
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
Male patients aged 18 years or older
Histologically confirmed prostate adenocarcinoma treated with radical prostatectomy
Biochemical recurrence after surgery defined by specific PSA criteria
No definite extrapelvic metastatic disease by conventional imaging within 26 weeks prior to registration
Eligible baseline PET/CT or PET/MR scan completed within 16 weeks prior to registration
Candidate for standard post-prostatectomy radiation therapy with androgen deprivation therapy
ECOG performance status of 0 to 2
Ability to understand and sign informed consent
No prior androgen deprivation therapy started before baseline PET imaging
Not enrolled in another therapeutic clinical trial
Able to tolerate PET scan and radiation therapy positioning
Meet institutional safety guidelines for PET/MR if applicable
No history of seizures or predisposing conditions within 1 year prior to registration
No history of inflammatory bowel disease or gastrointestinal disorder increasing radiation risk
Laboratory values within specified limits for blood counts, liver and kidney function
If HIV positive, on effective therapy with undetectable viral load within 6 months
Cardiac function classified as NYHA class I or II or equivalent
No prior pelvic radiation therapy
Agree not to father children during the study
English or Spanish speaking for quality of life assessments
You will not qualify if you...
Female patients
Patients younger than 18 years
Prior pelvic radiation therapy
History of seizures or conditions causing seizures within past year
Inflammatory bowel disease or gastrointestinal conditions increasing risk from radiation
Laboratory values outside required ranges
Not able to undergo PET or radiation therapy positioning
Enrolled in another therapeutic clinical trial
Unable to understand or sign informed consent
Patients with extrapelvic metastases not confirmed by PET or conventional imaging
Cardiac function worse than NYHA class II or equivalent
Not English or Spanish speaking if participating in quality of life assessments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 6 months
Participants receive combinations of standard external beam radiation, androgen deprivation therapies, apalutamide, and possibly targeted radiation based on PET scan results. Treatments generally last six months unless disease progresses or side effects occur.
Follow-up
Duration - Up to 10 years
After treatment, participants have regular follow-up visits every 3 months for 2 years, then every 6 months for years 3-5, and annually for years 6-10 to monitor disease status and quality of life.
Regular follow-up visits every 3 to 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Phase 1 Study of Lutetium Lu 177-PSMA-617 With or Without Sipuleucel-T for Men With Advanced Metastatic Castration-Resistant Prostate Cancer
Randomized Trial of Enzalutamide Plus Relacorilant Versus Placebo with Hormone Therapy for High-risk Localized Prostate Cancer
Randomized Study Comparing Lower Dose MR-Guided Radiation Therapy to Uniform Dose Treatment in Men With Prostate Cancer Using MR-Linac
Evaluating Exercise Therapy Versus Usual Care on Prostate Cancer Progression Markers in Men Under Active Surveillance
Study of Abemaciclib Followed by 177Lu-PSMA-617 to Treat Metastatic Castration-Resistant Prostate Cancer Previously Treated With Hormonal Agents and Chemotherapy
Improving Access to Genetic Testing for Underserved Cancer Patients Using a Multilingual Virtual Assistant
Improving Access to Survivorship Care with a Tailored Low Literacy Plan for African American Prostate Cancer Patients
Study of rhPSMA-7.3 PETCT POSLUMA Scan to Detect Recurrent Prostate Cancer in Men with Negative Prior PET PSMA Imaging
Phase 2 Trial of Relugolix to Enhance PSMA PETCT Imaging for High Risk Prostate Cancer
Randomized Study of Short-Term Androgen Deprivation Therapy and Diagnostic Improvement
Study of Blood Biomarkers to Predict Resistance to Androgen Receptor Inhibitors in Men With Metastatic Castration-Resistant Prostate Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski...